SCRIPPS/SANDOZ FINALIZED $100 MIL. AGREEMENT SLATED TO TAKE EFFECT IN 1997
Executive Summary
SCRIPPS/SANDOZ FINALIZED $100 MIL. AGREEMENT SLATED TO TAKE EFFECT IN 1997 with Sandoz Pharmaceuticals providing the Scripps Research Institute with yearly funding of $20 mil. over the next five years, Scripps announced May 16. Under the revised agreement, Sandoz will provide Scripps with $13 mil. per year in general funding and $7 mil. per year in specific funding -- a reduction from the original provision for $18 mil. of general and $12 mil. of specific funding annually. In the earlier agreement, Scripps would have received $300 mil. over a 10-year period from Sandoz. There is an option to extend the new contract for an additional five years.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth